S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Bio-Path Stock Forecast, Price & News

-0.02 (-0.33 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $6.10
50-Day Range
MA: $5.75
52-Week Range
Now: $6.10
Volume281,060 shs
Average Volume2.97 million shs
Market Capitalization$42.38 million
P/E RatioN/A
Dividend YieldN/A
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical trials for the treatment of chronic myeloid leukemia, as well as to treat solid tumors. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Bio-Path logo


88 Biggest Movers From Yesterday Benzinga - Benzinga
February 19, 2021 |  benzinga.com
Bio-Path slips 8% on capital raise - Seeking Alpha
February 16, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BPTH
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$7.31 per share


Net Income$-8,600,000.00


Market Cap$42.38 million
Next Earnings Date3/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.49 out of 5 stars

Medical Sector

480th out of 1,968 stocks

Pharmaceutical Preparations Industry

242nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
-0.02 (-0.33 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

Is Bio-Path a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Path?

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest in February. As of February 12th, there was short interest totaling 474,200 shares, an increase of 88.6% from the January 28th total of 251,400 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is presently 0.2 days.
View Bio-Path's Short Interest

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Bio-Path

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings data on Thursday, November, 19th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.03.
View Bio-Path's earnings history

How has Bio-Path's stock been impacted by COVID-19 (Coronavirus)?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BPTH stock has increased by 28.4% and is now trading at $6.10.
View which stocks have been most impacted by COVID-19

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path shares reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

1 brokerages have issued 12 month target prices for Bio-Path's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Bio-Path's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price.
View analysts' price targets for Bio-Path
or view top-rated stocks among Wall Street analysts.

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 72, Pay $490.16k)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 65, Pay $39.58k)
  • Mr. Anthony Price, Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D., MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant
  • Dr. Jeffery Lancet M.D., Consultant
  • Ms. Victoria Lake Rac, Regulatory Consultant

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.71%) and Virtu Financial LLC (0.48%).
View institutional ownership trends for Bio-Path

Which major investors are buying Bio-Path stock?

BPTH stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Bio-Path
or or view top insider-buying stocks.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $6.10.

How much money does Bio-Path make?

Bio-Path has a market capitalization of $42.38 million. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Bio-Path have?

Bio-Path employs 9 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

Where are Bio-Path's headquarters?

Bio-Path is headquartered at 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.